Sequenom Strengthens Executive Team with New Vice President of Sales
Medical Diagnostics Industry Veteran Will Help Drive Growth of Sequenom Laboratories Tests in New and Existing Channels

SAN DIEGO, April 12, 2016 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company committed to enabling healthier lives through the development of innovative products and services, is pleased to announce that Glenn Magnuson has joined the Company as Vice President of Sales, reporting to Rob Lozuk, Senior Vice President, Commercial Operations.  Mr. Magnuson has more than 25 years of experience in implementing effective sales processes, strategically managing accounts and realizing the revenue potential of medical diagnostic devices.

SEQUENOM logo.

"I'm delighted to welcome Glenn to Sequenom's executive team," said Dirk van den Boom, Ph.D., President and CEO of Sequenom.  "The three new tests we launched in 2015 and our entry in the average-risk pregnancy market provide Sequenom Laboratories with outstanding potential to expand its market presence, both for noninvasive prenatal tests as well as in carrier screening.  Glenn's proven record of motivating sales teams and facilitating long term business relationships in medical diagnostics and women's health is exactly what Sequenom Laboratories needs to expand its contribution to women's healthcare."

"With the broadest array of laboratory-developed tests in the industry, strong backing from maternal fetal medicine specialists, and its knowledgeable and professional sales team, Sequenom Laboratories is well-positioned to bring the benefits of noninvasive prenatal testing to as many patients as possible, including women with average-risk pregnancies," said Mr. Magnuson.  "My experience in medical diagnostics -- specifically including my background in women's health – is a great fit with Sequenom Laboratories' growth potential in this market."

Glenn Magnuson has 25 years of medical diagnostic sales experience, including immunology sales at Abbott Diagnostics; women's diagnostic tests at Cytyc / Hologic; and clinical chemistry, hematology, pathology, and molecular and point of care technologies at ThermoFisher Scientific.  Most recently, Mr. Magnuson was Vice President of Sales for T2 Biosystems, a leading provider of an FDA-approved Candida direct whole blood sepsis test.  He holds a Bachelor of Science degree in Business Administration from Bryant University in Rhode Island.

About Sequenom
Sequenom, Inc. (NASDAQ: SQNM) is a pioneering genetic testing company dedicated to women's health through the development of innovative products and services.  The Company serves patients and physicians by providing early patient management information.  For more information, visit www.sequenom.com.

About Sequenom Laboratories
Sequenom Laboratories, a CAP-accredited and CLIA-certified molecular diagnostics laboratory, has developed a broad range of laboratory tests, with a focus principally on prenatal care.  Branded under the names HerediT®, HerediT® UNIVERSAL, MaterniT® GENOME, MaterniT21® PLUS, NextView®, SensiGene® and VisibiliT™, these molecular genetic laboratory-developed tests provide early patient management information for obstetricians, geneticists, and maternal fetal medicine specialists.  Sequenom Laboratories is changing the landscape in genetic diagnostics using proprietary cutting edge technologies. Visit www.laboratories.sequenom.com and follow @SequenomLabs.

SEQUENOM®, HerediT®, MaterniT®, NextView®, SensiGene®, VisibiliT and Sequenom Laboratories are trademarks of Sequenom, Inc.  All other trademarks and service marks are the property of their respective owners.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 including statements regarding the development of innovative products and services, the ability to expand the Company's market presence for non-invasive prenatal tests and carrier screening and the ability to bring the benefits of noninvasive prenatal testing to as many patients as possible.  Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in the Company's filings with the Securities and Exchange Commission, including without limitation the Company's most recent Annual Report on Form 10-K and other documents subsequently filed with or furnished to the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Logo - http://photos.prnewswire.com/prnh/20160225/337675LOGO

 

SOURCE Sequenom, Inc.

For further information: Paul Goodson, Senior Director, Investor Relations and Corporate Communications, Sequenom, Inc., 858-202-9427, pgoodson@sequenom.com

print email rss pdf